Drug metabolism alterations in nonalcoholic fatty liver disease
about
Obesity: physiologic changes and implications for preoperative managementToxicant-associated steatohepatitisUse of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerationsHuman receptor activation by aroclor 1260, a polychlorinated biphenyl mixtureEvaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver diseaseDrug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Synergistic interaction between genetics and disease on pravastatin dispositionThe cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the ratBranched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Synergistic interaction between lipid-loading and doxorubicin exposure in Huh7 hepatoma cells results in enhanced cytotoxicity and cellular oxidative stress: implications for acute and chronic care of obese cancer patients.Bisphenol A sulfonation is impaired in metabolic and liver diseasePolychlorinated Biphenyl-Xenobiotic Nuclear Receptor Interactions Regulate Energy Metabolism, Behavior, and Inflammation in Non-alcoholic-Steatohepatitis.Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.Downregulation of sulfotransferase expression and activity in diseased human livers.Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development.Drug metabolism and liver disease: a drug-gene-environment interaction.Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.Thioacetamide-induced Hepatocellular Necrosis Is Attenuated in Diet-induced Obese Mice.Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?Perioperative management of the obese surgical patient.Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy.Protective effects of silymarin on triptolide-induced acute hepatotoxicity in rats.Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003-2010.Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study.Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice.Expression of cytochrome P450 mRNAs in Type II alveolar cells from subjects with chronic obstructive pulmonary disease.Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo.Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies.Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease
P2860
Q26830911-FB810A29-2608-45AB-BD35-15BB4D8F4A75Q27687049-6F0D966F-8DBF-4BF0-AFB2-E0A7955CCE43Q28072205-75D641DE-C817-4227-9D6E-63ABDE2AB81AQ28394850-C9766647-152A-4238-B1FB-05AD2FB20702Q28397356-DDA35BFB-F14F-4F89-B198-AF4AE339C986Q30241648-74525F42-61CB-449B-9E79-F8169AF3335CQ33729768-57EF70EB-7C56-47C2-BBE2-8A8CE28A0F5EQ33786577-75DD79D6-65E9-4DC3-9B13-AA997AC09B48Q34332185-36A0988F-7067-4609-A6FF-E3923E6AFA58Q34483949-61A38498-BBF3-43F0-BB18-46AFDE4507C1Q35085125-CF031F8F-26EF-482A-A9A7-A18B788CCF41Q35689076-ED7A6BEE-CA89-4298-85D3-DB740C4ED3D7Q36407635-2C5355B4-24A5-4F64-A91E-959CA4A0E8E1Q36495243-247FB60C-BC00-4680-AA7A-08FC5A53293BQ36573579-E50CF806-A8B5-4D7A-B796-F095A1BD41BEQ36642354-2906F6D5-AF06-4A81-A865-C620592A9B14Q37014966-905D8E47-D136-4AA8-8A5E-B2F031C7D573Q37422741-45B3739C-3C6B-4034-9435-FA333B5E0163Q37603899-A818EF86-CE34-4BA6-9358-6AAEE1079B34Q38681686-703ACAE5-6BE9-4432-96DD-990E76477454Q39037269-8B9985E7-52CF-4083-83D1-9CEA207639A2Q39111416-340DCB68-2796-4FF6-BBB7-DB4F0B9CA66DQ39183375-5B79C5FA-B298-4AC6-80DB-1A1652D74C9DQ41456158-6081FB94-856F-45B4-AFAA-717F6A1E24B9Q41523089-66E89F64-6ED3-49FB-ACED-09638DC2D66FQ42688154-71FC707A-37CD-4A3E-AF65-0DC8FBE1A510Q46440837-C1160421-0233-44DA-9723-E8647C1B143CQ47288317-A25D0DDF-DA94-4F55-84E5-D171306D3F7EQ47370372-AB05902A-52E0-46BC-B1F7-4A02BB2D2253Q48121439-B0FA6C4E-2069-4A6D-ABFB-04A578793F0DQ48264487-C60A56CB-5B22-4C40-8B59-0DDEDB4470FDQ50918622-24423BC2-F238-454D-8F61-0D5568CAE621Q55031591-C30C9682-CBE8-4658-A703-CD4E52B0F84DQ55154163-29FA06A5-9FC3-4777-992A-C3B20356CCB5Q55256317-362A246B-7899-45E7-8823-A3B9838F318AQ58417407-B8127A50-68D3-433D-A417-313B08DD9380
P2860
Drug metabolism alterations in nonalcoholic fatty liver disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug metabolism alterations in nonalcoholic fatty liver disease
@en
Drug metabolism alterations in nonalcoholic fatty liver disease.
@nl
type
label
Drug metabolism alterations in nonalcoholic fatty liver disease
@en
Drug metabolism alterations in nonalcoholic fatty liver disease.
@nl
prefLabel
Drug metabolism alterations in nonalcoholic fatty liver disease
@en
Drug metabolism alterations in nonalcoholic fatty liver disease.
@nl
P2860
P1476
Drug metabolism alterations in nonalcoholic fatty liver disease
@en
P2093
Matthew D Merrell
Nathan J Cherrington
P2860
P304
P356
10.3109/03602532.2011.577781
P407
P577
2011-05-25T00:00:00Z